Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Gordon J. Ruan"'
Autor:
Gordon J. Ruan, Xiaosheng Wu, Kimberly A. Gwin, Michelle K Manske, Jithma P. Abeykoon, Vaishali Bhardwaj, Taylor L. Witter, Matthew J. Schellenberg, Kari G Rabe, Neil E. Kay, Sameer A. Parikh, Thomas E. Witzig
Publikováno v:
Haematologica, Vol 999, Iss 1 (2024)
The open reading frame 8 (ORF8) protein, encoded by the SARS-CoV-2 virus after infection, stimulates monocytes/macrophages to produce pro-inflammatory cytokines. We hypothesized that a positive ex vivo monocyte response to ORF8 protein pre-COVID-19 w
Externí odkaz:
https://doaj.org/article/01329c39a20f4a1cb4a1181ddc685ff6
Autor:
Xiaosheng Wu, Michelle K. Manske, Gordon J. Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon, Xinyi Tang, Yue Yu, Kimberly A. Gwin, Annie Wu, Vanessa Taupin, Vaishali Bhardwaj, Jonas Paludo, Surendra Dasari, Haidong Dong, Stephen M. Ansell, Andrew D. Badley, Matthew J. Schellenberg, Thomas E. Witzig
Publikováno v:
iScience, Vol 26, Iss 6, Pp 106929- (2023)
Summary: Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates the life-threatening inflammatory cytokine response in patients with severe COVID-19 remains unidentified. Herein we demonstrate that the viru
Externí odkaz:
https://doaj.org/article/008c8e98333d4304b6e7fee69dec3a76
Autor:
Gordon J. Ruan, MD, Sangeetha Gandhi, MBBS, Jithma P. Abeykoon, MD, Susan Schram, PAC, Thomas M. Habermann, MD, Benjamin J. Sandefur, MD, Thomas E. Witzig, MD
Publikováno v:
Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol 5, Iss 2, Pp 423-430 (2021)
Objective: To distinguish between sepsis only vs progressive lymphoma in patients with a history of lymphoma who present to the hospital with lactic acidosis. Patients and Methods: We identified patients with non-Hodgkin lymphoma (NHL) or Hodgkin lym
Externí odkaz:
https://doaj.org/article/f51ae723ea874e6ebfcd90b44ee780f0
Autor:
Jennifer J. Gile, Camden L. Lopez, Gordon J. Ruan, Matthew A. Hathcock, Jithma P. Abeykoon, Joy R. Heimgartner, Nikola A. Baumann, M. Molly McMahon, Ivana N. Micallef, Patrick B. Johnston, Jose C. Villasboas Bisneto, Luis F. Porrata, Jonas Paludo, Stephen M. Ansell, William J. Hogan, Thomas E. Witzig
Publikováno v:
Blood Cancer Journal, Vol 11, Iss 3, Pp 1-9 (2021)
Abstract Magnesium is an essential element that is involved in critical metabolic pathways. A diet deficient in magnesium is associated with an increased risk of developing cancer. Few studies have reported whether a serum magnesium level below the r
Externí odkaz:
https://doaj.org/article/64d895b86c3842b0b58e9bd4963c7186
Autor:
Jithma P. Abeykoon, Paul J. Hampel, Rebecca L. King, Adam J. Wood, Melissa C Larson, Kevin E. Nowakowski, Saurabh S. Zanwar, Surendra Dasari, Gordon J. Ruan, Aishwarya Ravindran, Linda E. Wellik, Jonas Paludo, Brian K. Link, James R. Cerhan, Stephen M. Ansell, Grzegorz S. Nowakowski, Carrie A Thompson, Matthew J. Maurer, Kerstin Wenzl, Anne J. Novak, Xiaosheng Wu, Thomas M. Habermann, Thomas E. Witzig
Publikováno v:
Haematologica, Vol 106, Iss 8 (2021)
Externí odkaz:
https://doaj.org/article/4bbc3c43c423489c91c120dad843ed3f
Autor:
Antonious Z, Hazim, Aldo A, Acosta-Medina, Jason R, Young, Gordon J, Ruan, Jithma P, Abeykoon, Aishwarya, Ravindran, Robert, Vassallo, Jay H, Ryu, W Oliver, Tobin, Matthew J, Koster, N Nora, Bennani, Karen L, Rech, Mithun V, Shah, Thomas E, Witzig, Gaurav, Goyal, Ronald S, Go
Publikováno v:
British Journal of Haematology. 199:454-457
Autor:
Ashley Aaroe, Razelle Kurzrock, Gaurav Goyal, Aaron Michael Goodman, Harsh Patel, Gordon J Ruan, Gary Ulaner, Jason R. Young, Ziyi Li, Derek Dustin, Ronald S. Go, Eli L Diamond, Filip Janku
Publikováno v:
Blood Advances.
Erdheim-Chester disease (ECD) and Rosai-Dorfman disease (RDD) are rare non-Langerhans cell histiocytoses (non-LCHs) for which therapeutic options are limited. MAPK pathway activation through BRAFV600E mutation or other genomic alterations is a histio
Sustained, complete response to pexidartinib in a patient with CSF1R-mutated Erdheim-Chester disease
Autor:
Jithma P, Abeykoon, Terra L, Lasho, Surendra, Dasari, Karen L, Rech, Wasantha K, Ranatunga, Michelle K, Manske, Alexander, Tischer, Aishwarya, Ravindran, Jason R, Young, William Oliver, Tobin, Eoin P, Flanagan, Kevin E, Nowakowski, Gordon J, Ruan, Mithun V, Shah, Nabila Nora, Bennani, Robert, Vassallo, Jay H, Ryu, Matthew J, Koster, Caroline J, Davidge-Pitts, Mrinal M, Patnaik, Xiaosheng, Wu, Thomas E, Witzig, Gaurav, Goyal, Ronald S, Go
Publikováno v:
Am J Hematol
Erdheim-Chester disease (ECD) is a histiocytic neoplasm that predominantly harbors mitogen-activated protein kinase (MAPK) pathway variants. MAPK inhibitors typically are effective treatments, but mutations outside the MAPK pathway, such as CSF1R var
Autor:
Xiaosheng Wu, Michelle K. Manske, Gordon J. Ruan, Taylor L. Witter, Kevin E. Nowakowski, Jithma P. Abeykoon, Xinyi Tang, Yue Yu, Kimberly A. Gwin, Annie Wu, Vanessa Taupin, Vaishali Bhardwaj, Jonas Paludo, Surendra Dasari, Haidong Dong, Stephen M. Ansell, Andrew D. Badley, Matthew J. Schellenberg, Thomas E. Witzig
COVID-19 is a significant cause of morbidity and mortality in blood cancer patients, especially those on immunosuppressive therapy. Despite extensive research, the specific factor associated with SARS-CoV-2 infection that mediates the life-threatenin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bcaffd6955ded03bd44ff3e533144642
https://doi.org/10.1101/2021.12.02.470978
https://doi.org/10.1101/2021.12.02.470978
Autor:
Jithma P, Abeykoon, Karen L, Rech, Jason R, Young, Aishwarya, Ravindran, Gordon J, Ruan, Surendra, Dasari, Diana M, Morlote, Rebecca L, King, Claire, Rummage, Saurabh, Zanwar, Aldo M, Acosta-Medina, W Oliver, Tobin, Mithun V, Shah, N Nora, Bennani, Robert, Vassallo, Jay H, Ryu, Matthew J, Koster, Caroline J, Davidge-Pitts, Thomas E, Witzig, Gaurav, Goyal, Ronald S, Go
Publikováno v:
JAMA Oncology. 8:1816
ImportanceRosai-Dorfman disease (RDD) is a rare histiocytic neoplasm with recent studies showing alterations in the MAPK pathway, most commonly in the KRAS and MEK genes in about 40% of patients. Reports on the use of MEK-inhibitor therapy in RDD hav